/
EMBC
$3.31-$0.18 (-5.16%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$207.1M
59M shares
52-week range
$2.77 – $15.55
4% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.34%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-27.19
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.09B | $1.17B | $1.13B | $1.12B | $1.12B | $1.08B |
| Cost of revenue | $323.0M | $323.0M | $365.0M | $354.6M | $370.9M | $394.2M | $400.9M |
| Gross profit | $786.0M | $763.0M | $800.0M | $774.9M | $749.9M | $728.9M | $679.5M |
| Gross margin | 70.9% | 70.3% | 68.7% | 68.6% | 66.9% | 64.9% | 62.9% |
| R&D | $62.0M | $61.0M | $63.0M | $65.0M | $85.2M | $78.8M | $21.5M |
| Operating income | $502.0M | $487.0M | $492.0M | $378.1M | $229.6M | $174.2M | $329.3M |
| EBITDA | $536.0M | $524.0M | $533.0M | $334.5M | $245.4M | $199.0M | $294.7M |
| Net income | $432.0M | $427.6M | $414.8M | $223.6M | $70.4M | $78.3M | $95.4M |
| Net margin | 39.0% | 39.4% | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| EPS (diluted) | 7.58 | 7.50 | 7.31 | 3.89 | 1.22 | 1.34 | 1.62 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $1.59 | $1.55–$1.62 | 3 |
| 2027 | $1.1B | $1.74 | $1.73–$1.74 | 3 |
| 2028 | $1.1B | $1.93 | $1.42–$2.39 | 3 |
| 2029 | $1.1B | $2.96 | $2.95–$2.97 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$41.24
Price
$3.31
Implied upside
+1146%
Peer comparison
Embecta Corp. Common Stock
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
www.embecta.com- Employees
- 1,850
- IPO / List date
- Mar 21, 2022
- HQ
- PARSIPPANY, NJ
Held by traders on TradeandTell
No one on the platform currently holds EMBC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 144,287 | $1.3M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 13.90% ($0.46/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-28 | $0.0100 | 2026-06-15 |
| 2026-02-27 | $0.1500 | 2026-03-17 |
| 2025-12-05 | $0.1500 | 2025-12-18 |
| 2025-08-29 | $0.1500 | 2025-09-15 |
| 2025-05-28 | $0.1500 | 2025-06-13 |
| 2025-02-28 | $0.1500 | 2025-03-14 |
| 2024-12-06 | $0.1500 | 2024-12-18 |
| 2024-08-27 | $0.1500 | 2024-09-13 |
| 2024-05-24 | $0.1500 | 2024-06-14 |
| 2024-02-27 | $0.1500 | 2024-03-15 |
Recent trades on TradeandTell
No one on the platform has traded EMBC yet.
